AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines
AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
